如何跑出科技成果转化的"加速度"？与会专家表示，关键在于构建以企业为主体、以临床需求为导向、 产学研医深度融合的创新联合体与转化体系，系统破解转化链条中的堵点。 近日，以"Al for Health.助力健康中国2030"为主题的第二届海医汇医疗科技创新生态大会在北京举办。 会议由中国研究型医院学会、中国医学科学院北京协和医学院、广州实验室主办。专家学者及业界代表 在会议期间共同探讨在AI与科技驱动下，科研成果如何实现从实验室"种子"转为产业化"果实"，精准对 接科研与临床需求。 发表于《药品评价》期刊的《转化医学——药物研发的新契机》一文数据显示，我国每年医学科技成果 转化率低于8%，许多科学研究与专利技术停留于实验室层面。 "大力推动医学科技创新生态建设，需要构建开放共赢的协同机制，打破数据壁垒、学科壁垒、机构壁 垒，让创新要素自由流动。"大会上，中国研究型医院学会会长何振喜建议，需要推动医、研、政、 企、资多方实现信息共享与资源整合，构建起创新成果快速转化、良性循环的医疗科技创新生态。 中国工程院院士、中国医学科学院北京协和医学院院校长吉训明表示，要构建起"医工共创"的高效模 式，助力研究人员在潜心治学 ...

Group 1 - The company, Taimei Medical Technology, has established a partnership agreement to form a partnership enterprise with an initial total investment of RMB 227.27 million from various partners [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership enterprise will primarily invest in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership enterprise will allow the company to deeply engage in the research and development of innovative drug pipelines [2] - The company aims to standardize and modularize its digital pharmaceutical R&D solutions for early to growth-stage innovative drug development pipelines, potentially sharing in the excess returns from successful drug development [2] - By holding pipeline rights through the partnership, the company can participate in early clinical trials, thus avoiding the complexities and long-term risks associated with traditional equity investments [2]

Core Insights - Zhongkang Holdings (02361.HK) has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors including marketing, healthcare, pharmacies, and consumer management [1] Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tiangong No. 1 · Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Healthcare - In the healthcare sector, the company has developed the "Zhuomuniao Medical Large Model" and launched the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors to enhance the quality of decision-making in complex medical diagnoses [2] Pharmacies - In the pharmacy sector, the company has introduced an intelligent agent that has served over 10,993 pharmacies, utilizing comprehensive industry data to establish a matrix of five AI intelligent agents covering operational insights, products, diseases, members, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to empower store operations [3] Consumer Management - In health management, the company has created a matrix of AI intelligent agents covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [4]

近日，"AI for Health助力健康中国2030——第二届海医汇医疗科技创新生态大会"在北京隆重举行。作为海尔集团旗下大健康生态品牌，盈康一生携医工转 化核心成果亮相，与产、学、研、医、资领域顶尖力量共探AI时代医疗创新路径，为破解"实验室到病床"转化难题输出"中国范式"，彰显了领军企业在大健 康产业升级中的核心担当。 战略承接者，打造融合创新的生态系统 当前，"健康中国2030"纵深推进，国家卫健委等多部门明确2030年基层诊疗智能辅助应用基本全覆盖，"十五五"规划更为医疗科技注入发展动能。但政策红 利下，行业痛点凸显：我国医学成果转化率不足8%，远低于欧美70%的水平，大量科研成果困于"实验室到病床"的"达尔文之海"…… 国家战略的落地需要企业作为"产业转换器"。盈康一生主动承接这一国家战略需求，牵头打造了全国首个医工科技产业化平台"海医汇"。海尔集团董事局副 主席、执行副总裁，盈康一生董事长，海医汇理事长谭丽霞表示，海医汇致力于做这个时代能够把一切组织起来的链接者和加速者，希望面向中国医疗创新 的未来，打造一种融合创新的生态系统。 经过一年实践，海医汇已构建起"临床需求-技术研发-成果转化-产业应 ...

人民财讯12月24日电，企查查APP显示，近日，广西优必选医疗科技有限公司成立，法定代表人为王 琳，经营范围包含：物联网技术研发；第一类医疗器械销售；智能机器人的研发；智能机器人销售；软 件开发；软件销售等。企查查股权穿透显示，该公司由优必选间接全资持股。 ...

近日，智医向量成功完成数千万人民币 Pre-A 轮融资，由正轩投资公司投资。正轩投资是一家专注于高 科技与创新型企业投资的专业机构，重点布局先进制造、人工智能及机器人、新能源、新材料、半导 体、航空航天等领域，正轩投资董事长夏佐全先生为比亚迪创始人之一。本轮融资将主要用于加速"意 识大模型医疗健康机器人"技术体系的研发迭代、全球市场拓展以及高端人才引进。 朱想是现任广州智医向量云科技有限公司首席执行官。在创立智医向量云之前，他受聘担任巴黎十二大 LISSI实验室（Université Paris-Est Créteil, UPEC）LISSI（Laboratoire Images, Signaux et Systèmes Intelligents) 研究员，专注于医疗知识图谱、语言大模型等科研工作。此前，他曾作为微大夫联合创始 人，和创始团队一起成功实现多轮融资估值达5亿美元。朱想也曾任职于美国通用电气（GE）医疗和 HP惠普，担任产品研发负责人和工程师。 朱想目前同时是巴黎大学及华南理工大学机器学习与神经网络方向的博士，他已在核心期刊会议上发表 多篇论文，获得多项医疗人工智能相关专利。 其他创始团队成员来自 ...

Core Insights - The article highlights that Zhiyun Health (09955.HK) won the "Annual Transformation Pioneer Award" for its outstanding performance in strategic transformation, business restructuring, and sustainable growth [1][4] - The award recognizes companies that achieve high-quality development and create long-term value through proactive changes in a dynamic market environment [1] Strategic Focus and Financial Transformation - Zhiyun Health has shifted from a scale expansion model to a focus on "AI SaaS + P2M" for high-quality growth [4] - The company has divested non-core businesses, such as medical supplies, to concentrate resources on digital chronic disease management, marking a strategic focus rather than mere contraction [5] Financial Performance - In the first half of 2025, Zhiyun Health reported a 20.3% year-on-year revenue growth after excluding the impact of divested businesses, demonstrating resilience in core business growth [6] - The gross margin reached 37.1%, an increase of over 16 percentage points year-on-year, indicating a successful shift from scale-driven to quality-driven business [6] - The company achieved a historic positive operating cash flow of 28.65 million yuan, marking its first positive cash flow since listing, validating its high-value strategy [7] AI SaaS + P2M Dual-Engine Model - Zhiyun Health has developed a dual-engine model of "AI SaaS + P2M," which enhances its business transformation and provides a sustainable core momentum [9] - The company's SaaS systems cover over 2,700 hospitals and nearly 270,000 pharmacies, establishing a vast digital service network that supports data accumulation and patient insights [10] - The P2M model generated 260 million yuan in revenue in the first half of 2025, a 142.1% year-on-year increase, and has become a profitable growth driver [11] Technological Advancements - The company continues to explore core technologies, with its self-developed "Zhiyun Medical Brain" and various AI models enhancing operational efficiency and aiding in diagnosis and research [12] - The integration of advanced AI technology is crucial for the effective operation of the dual-engine model and building long-term competitive barriers [12] Future Outlook - With the recognition of the "Annual Transformation Pioneer Award," Zhiyun Health has successfully transitioned from a digital service provider to a chronic disease management ecosystem re-builder [14] - The company aims to solidify its leading position in digital chronic disease management while leveraging technology to reconstruct medical value and empower the future of the industry [14]

Core Viewpoint - The company, Brain Dynamics Aurora-B (06681), has seen its stock price increase by over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Project Involvement - The company’s wholly-owned subsidiary, Smart Genius Technology, is a key collaborator in the national major science and technology project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project specifically addresses the challenges in diagnosing cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS) and aims to establish a deep reasoning model and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] Group 2: Technological Development - As a core technology unit, the company will be responsible for the development of the deep reasoning model related to cognitive disorders caused by ICAS and the construction of a digital diagnosis and treatment platform [1] - The project has recently been officially launched, indicating a significant step forward in the company's technological capabilities and contributions to the healthcare sector [1] Group 3: Collaboration and Recognition - Smart Genius Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders," which has also been officially approved [1] - This collaboration highlights the company's commitment to advancing research and development in the field of cognitive health and its strategic partnerships with leading medical institutions [1]

Core Viewpoint - Brain动极光-B (06681) has seen a stock price increase of over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Company Developments - Brain动极光's wholly-owned subsidiary, 智精灵科技, is a key collaborator in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases," specifically focusing on cognitive disorders related to intracranial atherosclerotic stenosis [1] - The project aims to establish key technologies for digital diagnosis and treatment of cognitive disorders, utilizing deep reasoning large models and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] - 智精灵科技 has also recently received approval for the establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital [1] Group 2: Industry Context - The national technology major project addresses the clinical challenges of diagnosing and treating cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS), indicating a growing focus on advanced digital health solutions in the medical field [1] - As a core technology provider, Brain动极光 is tasked with the development of deep reasoning models related to cognitive disorders and the construction of a digital diagnosis and treatment platform, highlighting the company's strategic positioning in the healthcare technology sector [1]

来源：市场资讯 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一类医疗器械销售； 第二类医疗设备租赁；第一类医疗设备租赁；第一类医疗器械生产；专用设备修理；专用设备制造（不 含许可类专业设备制造）；第二类医疗器械销售；智能机器人的研发；人工智能行业应用系统集成服 务；可穿戴智能设备销售；可穿戴智能设备制造；软件开发；智能机器人销售。（除依法须经批准的项 目外，凭营业执照依法自主开展经营活动）许可项目：医疗器械互联网信息服务；第三类医疗设备租 赁；第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营。（依法须经批准的项目，经相 关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 企业名称韶脑（上海）医疗科技有限公司法定代表人郑思羽注册资本500万人民币国标行业科学研究和 技术服务业>研究和试验发展>工程和技术研究和试验发展地址上海市闵行区联友路118弄4号803室企业 类型有限责任公司（自然人投资或控股的法人独资）营业期限2025-12-23至无固定期限登记机关闵行区 市场监督管理局 天眼查显示，近日，韶脑（上海）医疗科技有限公司成立，法定代表人为郑思羽 ...